Requip tablets treat symptoms of primary RLS
Research Triangle Park, NC (December 15, 2004) Study results published today in the journal Movement Disorders show that Requip(ropinirole HCl) Tablets effectively treats the symptoms of primary Restless Legs Syndrome (RLS) as assessed by improvements in symptoms, over 12 weeks. Improvements were seen as early as one week. The study of 267 patients, one of the largest placebo-controlled trials...GSK'S Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
Philadelphia, PA (August 1, 2004) New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), have fewer awakenings resulting from involuntary kicks when treated with GlaxoSmithKline's Requip (ropinirole HCl). Patients also reported better sleep adequacy as defined by feeling rested upon wakin...ReQuip cuts risk of dyskinesias by 15-fold in early Parkinson's disease
.Vancouver, Canada - A landmark, multinational, 5-year.study shows that the dopamine-agonist ReQuip® (ropinirole hydrochloride,.SmithKline Beecham) is associated with a much lower incidence of dyskinesias .than L-dopa, and has comparable efficacy to L-dopa in the management of early.Parkinson's Disease. The results of this exciting study are released today for.the first time at the XIII In...